Return to Listing

3 result(s) for

PI Name Protocol # Title
Zahi Mitri STUDY00018504 A Phase II, Open Label, Study of Olaparib and Durvalumab in Patients with Metastatic Triple Negative Breast Cancer
Jeremy Cetnar STUDY00019101 STUDY OF DURVALUMAB OR DURVALUMAB AND TREMELIMUMAB AS CONSOLIDATION TREATMENT FOR PATIENTS WITH LIMITED STAGE SMALL-CELL LUNG CANCER WHO HAVE NOT PROGRESSED FOLLOWING CONCURRENT CHEMORADIATION THERAPY (ADRIATIC)
Shivaani Kummar STUDY00021464 A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080